Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance

Molecular Pharmacology

Volumn 50, Issue 6, 1996, Pages 1536-1540

  Vasey, Paul A ^a   Jones, Neil A ^b   Jenkins, Sheila ^a   Dive, Caroline ^b   Brown, Robert ^a,c  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CRC Department of Medical Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CISPLATIN; CYTARABINE; DOXORUBICIN; PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SUBPOPULATION; CLONOGENESIS; CROSS RESISTANCE; DNA DAMAGE; HUMAN; HUMAN CELL; IONIZING RADIATION; MULTIDRUG RESISTANCE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; THYMOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CISPLATIN; DRUG RESISTANCE, MULTIPLE; GENES, P53; HUMANS; MICE; PACLITAXEL; THYMUS GLAND; TUMOR CELLS, CULTURED;

EID: 0030465009     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311 (1991).
2. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie. Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature (Lond.) 362:849-852 (1993).
3. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967 (1993).
4. McIlwrath, A. J., P. A. Vasey, G. M. Ross, and R. Brown. Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 54:3718-3722 (1994).
5. Slichenmyer, W. J., W. G. Nelson, R. J. Slebos, and M. B. Kastan. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168 (1993).
6. Brown, R., C. Clugston, P. Burns, A. Edlin, P. Vasey, B. B. Vojtesek, and S. B. Kaye. Increased accumulation of p53 in cisplatin-resistant ovarian cell lines. Int. J. Cancer 55:678-684 (1993).
7. Fan, S., M. L. Smith, D. J. Rivet, D. Duba, Q. Zhan, K. W. Kohn, A. J. Fornace, and P. M. O'Connor. Disruption of p53 function sensitises breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55:1649-1654 (1995).
8. Wang, Y., L. Szekely, I. Okan, G. Klein, and K. G. Wiman. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427-3431 (1993).
9. Hamaguchi, K., A. K. Godwin, M. Yakushiji, P. J. O'Dwyer, R. F. Ozols, and T. C. Hamilton. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 53: 5225-5232 (1993).
10. McGuire, W. P. Ovarian cancer, in Paclitaxel in Cancer Treatment (W. P. McGuire and E. K. Rowinsky, eds.). Dekker, New York, 201 (1995).
11. Rowinsky, E., R. Donehower, N. Rosensheim, J. Walczak, W. McGuire. A Phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 36:275 (1995).
12. Evans, D. L., and C. Dive. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and non-proliferating immature thymocytes. Cancer Res. 53:2133-2139 (1993).
13. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, J. S. Butel, and A. Bradley. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.) 356:215-221 (1992).
14. Evans, D. L., M. Tilby, and C. Dive. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the level of drug accumulation and DNA adduct formation. Cancer Res. 54:1596-1603 (1994).
15. Cohen, G. M., X. Sun, R. T. Snowden, M. G. Ormerod, and D. Dinsdale. Identification of a transitional preapoptotic population of thymocytes. J. Immunol. 151:566-574 (1993).
16. Larsen, J. K. Measurement of cytoplasmic and nuclear antigens, in Flow Cytometry: A Practical Approach (M. G. Ormerod, ed.). Oxford University Press, London (1994).
17. Sun, X., R. T. Snowden, D. N. Skilleter, D. Dinsdale, M. G. Ormerod, and G. M. Cohen. A flow cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal. Biochem. 204:351-356 (1992).
18. Hsiang, L., M. G. Lihou, and L. F. Liu. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082 (1989).
19. Slichenmyer, W. J., E. K. Rowinsky, R. C. Donehower, and S. H. Kaufmann. The current status of camptothecin analogues as antitumour agents. J. Natl. Cancer Inst. 85:271-291 (1993).
20. Wahl, A. F., K. L. Donaldson, C. Fairchild, F. Y. F. Lee, S. A. Foster, G. W. Demers, and D. A. Galloway. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:72-79 (1996).
21. Strasser, A., A. W. Harris, T. Jacks, and S. Cory. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by bcl-2. Cell 79:329-339 (1994).
22. Righetti, S. C., G. D. Torre, S. Pilotti, S. Menard, F. Ottone, M. I. Colnaghi, M. A. Pierotti, C. Lavarino, M. Cornarotti, S. Oriana, S. Bohm, G. L. Bresciani, G. Spatti, and F. Zunino. A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:689-693 (1996).
23. Al-Azraqi, A., C. Chapman, C. Challen, J. Sigalas, S. Aswaad, D. Sinha, A. H. Calvert, and J. Lunec. P53 alterations in ovarian cancer as a determinant of reponse to carboplatin. Br. J. Cancer 69: 7 (1994)